J R Hecht, S S Raman, A Chan, K Kalinsky, J-F Baurain, M M Jimenez, M M Garcia, M D Berger, U M Lauer, A Khattak, A Carrato, Y Zhang, K Liu, E Cha, A Keegan, S Bhatta, C P Strassburg, A Roohullah
BACKGROUND: Talimogene laherparepvec (T-VEC), a first-in-class oncolytic viral immunotherapy, enhances tumor-specific immune activation. T-VEC combined with atezolizumab, which blocks inhibitor T-cell checkpoints, could provide greater benefit than either agent alone. Safety/efficacy of the combination was explored in patients with triple negative breast cancer (TNBC) or colorectal cancer (CRC) with liver metastases. METHODS: In this phase Ib, multicenter, open-label, parallel cohort study of adults with TNBC or CRC with liver metastases, T-VEC (106 then 108 PFU/ml; ≤4 ml) was administered into hepatic lesions via image-guided injection every 21 (±3) days...
February 28, 2023: ESMO Open